Idorsia holds its Annual General Meeting of Shareholders
- All Board proposals approved by the Shareholders
Allschwil, Switzerland – May
4,
2023At today’s Annual
General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel,
Switzerland, shareholders voted in favor of all proposals by the
Board of Directors with a significant majority.
The meeting was attended by 146 shareholders, representing a
total of 89’693’506 shares, or 47.73 % of the total outstanding
shares.
Led by the Chairman of the Board, Mathieu Simon, and by the
Chief Executive Officer, Jean-Paul Clozel, the company presented
the highlights of 2022.
Mathieu Simon, MD, Chairman of the
Board of Directors of Idorsia, commented:“Idorsia has made
significant progress in a short period, transforming from a
clinical-stage company to a fully-fledged biopharmaceutical company
with products available in multiple major markets. It is reassuring
to see that such a high majority of our shareholders appreciate the
company’s achievements and have given the management and Board
their endorsement through their votes. I want to say thank you to
the shareholders for their confidence, I’m sure that as the company
executes on its strategic priorities they will be rewarded.”
The shareholders approved the Annual Report 2022, together with
the Statutory and the Consolidated Financial Statements for 2022.
Shareholders also endorsed the 2022 compensation report by way of
consultative vote.
The shareholders approved the appropriation of available
earnings and that the net loss for the year 2022 be carried
forward.
The shareholders granted discharge to all members of the Board
of Directors and of the Executive Management for the financial year
2022.
The shareholders re-elected all Board members and elected Dr.
Sophie Kornowski as a new Board member for a term of office until
the conclusion of the AGM 2024. In addition, the shareholders
elected Mathieu Simon as Chairman of the Board, and Felix R. Ehrat
(Committee Chair), Srishti Gupta, Mathieu Simon, and Sophie
Kornowski to the Nominating, Governance and Compensation
Committee.
Following the AGM, the Board of Directors of Idorsia comprises a
total of 8 members: Mathieu Simon (Chairman), Jean-Paul Clozel,
Jörn Aldag, Felix R. Ehrat, Srishti Gupta, Peter Kellogg, Sophie
Kornowski, and Sandy Mahatme.
Shareholders approved the aggregate maximum compensation for the
Board of Directors (Non-Executive Directors) for the term until the
AGM 2024 and the aggregate compensation amount for the Idorsia
Executive Committee (IEC) for the financial year 2024.
BachmannPartner AG, who was represented by Mr Alain Bachmann,
was re-elected as Independent Proxy for a term of office until the
conclusion of the AGM 2024.
Ernst & Young was re-elected as the company's statutory
auditors for the business year 2023.
Finally, on January 1, 2023, the Swiss corporate law reform
entered into force. Shareholders approved all amendments to the
company Articles of Association, meaning that Idorsia is now
compliant with the new Swiss corporate law.
Notes to the editor
About IdorsiaIdorsia Ltd is reaching out for
more – We have more ideas, we see more opportunities and we want to
help more patients. In order to achieve this, we will develop
Idorsia into a leading biopharmaceutical company, with a strong
scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub –
Idorsia is specialized in the discovery, development and
commercialization of small molecules to transform the horizon of
therapeutic options. Idorsia has a 20-year heritage of drug
discovery, a broad portfolio of innovative drugs in the pipeline,
an experienced team of professionals covering all disciplines from
bench to bedside, and commercial operations in Europe, Japan, and
the US – the ideal constellation for bringing innovative medicines
to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol:
IDIA) in June 2017 and has over 1,300 highly qualified specialists
dedicated to realizing our ambitious targets.
For further information, please contactAndrew
C. WeissSenior Vice President, Head of Investor Relations &
Corporate CommunicationsIdorsia Pharmaceuticals Ltd,
Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10
10www.idorsia.com
The above information contains certain "forward-looking
statements", relating to the company's business, which can be
identified by the use of forward-looking terminology such as
"estimates", "believes", "expects", "may", "are expected to",
"will", "will continue", "should", "would be", "seeks", "pending"
or "anticipates" or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions
of the company's investment and research and development programs
and anticipated expenditures in connection therewith, descriptions
of new products expected to be introduced by the company and
anticipated customer demand for such products and products in the
company's existing portfolio. Such statements reflect the current
views of the company with respect to future events and are subject
to certain risks, uncertainties and assumptions. Many factors could
cause the actual results, performance or achievements of the
company to be materially different from any future results,
performances or achievements that may be expressed or implied by
such forward-looking statements. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated or
expected.
Idorsia (LSE:0RQE)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Idorsia (LSE:0RQE)
Gráfica de Acción Histórica
De May 2023 a May 2024